Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Precigen, Inc.NASDAQ: PGEN
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $3.58M rose 118.6% year over year, ahead of the +42.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 19.1% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Stock-based compensation amounted to 112.2% of revenue in FY2025, down 129.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +118.6% holds above the trailing-twelve-month pace of +42.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.87M USD
- Year-over-year change
- +14.7%
- 4-year CAGR
- -6.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.87M | +14.7% |
| FY2024 | 2024-12-31 | 9.47M | -4.2% |
| FY2023 | 2023-12-31 | 9.89M | -3.1% |
| FY2022 | 2022-12-31 | 10.21M | -26.6% |
| FY2021 | 2021-12-31 | 13.9M | — |
Stock-Based Compensation vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 stock-based compensation of $13.14M is the 5th largest of the 8 companies compared; the peer median is $34.64M.
- Its year-over-year change of +42.2% is the highest of 8, against a peer median of -8.8%.
- Stock-based compensation amounts to 15.3% of revenue for PGEN, versus a peer median of 48.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.91M | +2.8% | +19.1% | 220.8% | |
| LTM Sep 2026 | $69.68M | -8.8% | -9.5% | 276.8% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Jun 2026 | $13.14M | +42.2% | +2.1% | 15.3% | |
| LTM Mar 2026 | $9.12M | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $8.91M | -28.8% | -19.0% | 19.8% | |
| LTM Mar 2026 | $8.33M | +7.1% | +52.3% | 57.3% | |
| Peer median (excluding PGEN) | $34.64M | -8.8% | -5.4% | 48.4% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| Deferred Income Tax | (167K) | (150K) | (479K) | (1.8M) | 0 |
| Stock-Based Compensation | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M |
| Change in Working Capital | (804K) | (35.7M) | 17.07M | 4.52M | 6.62M |
| Accounts Receivables | (6.56M) | (13.51M) | 12.23M | 414K | (3.2M) |
| Inventory | (1.9M) | 2.34M | 0 | 0 | (9.21M) |
| Accounts Payables | 420K | 379K | (2.42M) | 1.55M | 8.77M |
| Other Working Capital | 7.24M | (24.91M) | 7.26M | 2.56M | 10.26M |
| Other Non-Cash Items | 9.7M | (78.48M) | (4.17M) | 41.34M | 142.12M |
| Operating Cash Flow | (55.77M) | (65.05M) | (66.93M) | (68.17M) | (87.83M) |
| Capital Expenditures | (7.25M) | (4.92M) | (1.54M) | (8.58M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (174.22M) | 0 | (185.03M) | (187.21M) | (208.01M) |
| Sales of Investments | 100.17M | 68.44M | 183.38M | 175.02M | 208.47M |
| Other Investing Activities | 6.76M | 162.9M | 98K | 60K | 0 |
| Investing Cash Flow | (74.54M) | 226.42M | (3.09M) | (20.71M) | (1.54M) |
| Debt Repayment | (466K) | (155.29M) | (43.22M) | 0 | 92.82M |
| Common Stock Issued | 121.05M | 0 | 72.81M | 31.24M | 310K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 608K | 1K | 0 | 346K | (3.08M) |
| Financing Cash Flow | 121.19M | (155.29M) | 29.59M | 110.58M | 90.05M |
| Effect of Forex Changes | 217K | (827K) | (320K) | (27K) | 35K |
| Net Change in Cash | (8.91M) | 5.25M | (40.75M) | 21.67M | 717K |
| Free Cash Flow | (63.02M) | (69.97M) | (68.47M) | (76.76M) | (89.83M) |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.